Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers

ABSTRACTThe evidence on the waning protection of COVID-19 vaccines has been reviewed by the World Health Organization and has led to consideration of the need for booster doses. This study aimed to evaluate vaccine effectiveness against COVID-19, and the COVID-19 infections among healthcare workers...

Full description

Saved in:
Bibliographic Details
Main Authors: Hazal Cansu Çulpan (Author), Sümeyye Nur Aydın (Author), Abdulkerim Uygur (Author), Uğurcan Sayılı (Author), Erkam Şeker (Author), İ̇lker İnanç Balkan (Author), Rıdvan Karaali (Author), Beyhan Budak (Author), Yılmaz Keskindemirci (Author), Neşe Saltoğlu (Author), Günay Can (Author)
Format: Book
Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACTThe evidence on the waning protection of COVID-19 vaccines has been reviewed by the World Health Organization and has led to consideration of the need for booster doses. This study aimed to evaluate vaccine effectiveness against COVID-19, and the COVID-19 infections among healthcare workers who received various types (inactive or m-RNA) and doses (2 to 4 doses) of the COVID-19 vaccine. The study was conducted with a total of 3,009 healthcare workers between August 1 and November 30, 2021 at a university hospital. Six different vaccination statuses were evaluated in the study. The effectiveness for COVID-19 infection, after adjusting for age, sex, and position, was highest in those who received two doses of CoronaVac and two doses of BNT162b2 (89.3%, 95% CI 72.2-95.9%) and was lowest in those who received two doses of CoronaVac (29%, 95% CI − 8-53%). The adjusted effectiveness of two doses of CoronaVac for COVID-19 infection was not significant (21.0%, 95% CI − 20.7-48.3%) but increased significantly with a booster dose of CoronaVac or BNT162b2. One or two doses of the BNT162b2 booster demonstrated higher effectiveness in comparison to a single dose of the CoronaVac booster. These results indicate the need for a booster dose, and heterologous boosting with BNT162b2 may be a better option for higher effectiveness for those who received two doses of CoronaVac. Future studies should evaluate the need for further booster doses and their long-term effects.
Item Description:10.1080/21645515.2023.2275445
2164-554X
2164-5515